Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma

• Published in: Journal of allergy and clinical immunology Vol. 143; no. 3; pp. 970 - 977
• Main Authors: Pfaar, Oliver, Bachert, Claus, Kuna, Piotr, Panzner, Petr, Džupinová, Mária, Klimek, Ludger, van Nimwegen, Maroesja J., Boot, Johan D., Yu, Donghui, Opstelten, Dirk Jan E., de Kam, Pieter-Jan
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2019; Elsevier Limited
• Subjects: Adolescent; Adult; Aged; allergen immunotherapy; Allergens; Allergens - immunology; allergic rhinoconjunctivitis; Allergies; Antigens, Plant - immunology; Asthma; Asthma - therapy; Betula - immunology; Birch pollen allergy; Clinical trials; combined symptom and medication score; Conjunctivitis, Allergic - therapy; Double-Blind Method; Drug therapy; efficacy; Female; Humans; Immunology; Immunotherapy; Male; Medicin och hälsovetenskap; Middle Aged; Oral administration; Patients; pivotal phase III trial; Pollen; Pollen - immunology; Population; Quality of life; Rhinitis, Allergic, Seasonal - therapy; Rhinoconjunctivitis; Safety; Seasons; sublingual immunotherapy; Sublingual Immunotherapy - adverse effects; Treatment Outcome; Young Adult; Netherlands; PP; allergic rhinoconjunctivitis; dSS; ITT; CSMS; dMS; safety; EMA; AUN; EAACI; RQLQ; SLIT; allergen immunotherapy; AE; pivotal phase III trial; combined symptom and medication score; AIT; efficacy; EQ-VAS; ACQ; ARC; TEAE; sublingual immunotherapy; quality of life; Birch pollen allergy

Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both clinically efficacious and safe. However, in line with the current regulatory guidance from the European Medicines Agency, allergen immunotherapy (AIT) products must demonstrate their efficacy and safety in pivotal phase III t...